62300-07-6

Basic information

• Product Name: Benzeneacetyl chloride, 2-iodo-
• CAS NO: 62300-07-6
• Molecular Formula: C8H6ClIO
• Molecular Weight: 280.493
• Mol File: 62300-07-6.mol
• Article Data: 26

Chemical Properties

• CAS DataBase Reference: Benzeneacetyl chloride, 2-iodo-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetyl chloride, 2-iodo-(62300-07-6)
• EPA Substance Registry System: Benzeneacetyl chloride, 2-iodo-(62300-07-6)

Safety Data

• Hazardous Substances Data: 62300-07-6(Hazardous Substances Data)

Upstream product

• 52470-94-7 (2-iodophenyl)diazomethyl ketone 
• 59473-45-9 2-(chloromethyl)iodobenzene 
• 40400-15-5 2-(2-iodophenyl)acetonitrile 
• 18698-96-9 o-iodophenylacetic acid 

Downstream Products

• 93769-24-5 1-<2-(1-Propin-1-yl)phenyl>-2-propanon 
• 93769-04-1 1-methylene-2-<2-(1-propyn-1-yl)phenyl>ethyl triflate 
• 93769-03-0 (Z)-1-methyl-2-<2-(1-propyn-1-yl)phenyl>vinyl triflate 
• 93769-02-9 (E)-1-methyl-2-<2-(1-propyn-1-yl)phenyl>vinyl triflate 
• 1607795-80-1 C₁₄H₁₉NO 
• 1607795-82-3 C₁₂H₁₅NO₂ 
• 1607795-83-4 C₁₄H₁₉NO₂ 
• 1607795-98-1 C₁₄H₁₉NO₂ 

Relevant articles and documents

Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.

FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY

A compound of formula (I): which inhibits the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1 and MOF.

6π/10π-Electrocyclization of ketene-iminium salts for the synthesis of substituted naphthylamines

An intramolecular 6π/10π-electrocyclization from ketene-iminium salts was developed for the preparation of naphthylamines. Various substituents on the nitrogen, on the aromatic ring, and on the olefin were studied. Tricyclic skeletons were obtained in few steps and good overall yields. The electrocyclization of ketene-iminium salts has been computationally explored by means of DFT calculations and their activation barriers were compared to the parent triene as well as the corresponding dienyl allenes and dienyl ketenes. Electrocyclizations for ketene-iminium salts were shown to be highly exergonic and have much smaller barriers to activation.